Cargando…

Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?

Cholesteryl ester transfer protein (CETP) inhibitors significantly increase serum high-density lipoprotein cholesterol (HDL) cholesterol levels and decrease low-density lipoprotein cholesterol (LDL) cholesterol concentration. However, three drugs of this class failed to show a decrease of cardiovasc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Filippatos, Theodosios D., Kei, Anastazia, Elisaf, Moses S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750532/ https://www.ncbi.nlm.nih.gov/pubmed/28961179 http://dx.doi.org/10.3390/diseases5040021

Ejemplares similares

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
por: Moutzouri, Elisavet, et al.
Publicado: (2010)

Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia
por: Kei, Anastazia, et al.
Publicado: (2014)

Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib
por: Miyares, Marta A, et al.
Publicado: (2012)

Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case
por: Johns, Douglas G., et al.
Publicado: (2019)

Thiazide–associated hyponatremia in the elderly: what the clinician needs to know
por: Liamis, George, et al.
Publicado: (2016)

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects
por: Thomas, Tiffany, et al.
Publicado: (2017)

Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes
por: Christopoulou, Eliza, et al.
Publicado: (2019)

Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E
por: Millar, John S., et al.
Publicado: (2017)

Hyponatremia in the elderly: challenges and solutions
por: Filippatos, Theodosios D, et al.
Publicado: (2017)

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou, Ioanna, et al.
Publicado: (2019)

Anacetrapib as a potential cardioprotective strategy
por: Di Bartolo, Belinda A, et al.
Publicado: (2017)

Non-hemorrhage-related adverse effects of rivaroxaban
por: Christopoulou, Eliza C., et al.
Publicado: (2017)

Electrolyte and acid-base disorders in inflammatory bowel disease
por: Barkas, Fotis, et al.
Publicado: (2013)

Editorial: Secondary Dyslipidemias
por: Elisaf, Moses, et al.
Publicado: (2011)

Impact of ADCY9 Genotype on Response to Anacetrapib
por: Hopewell, Jemma C., et al.
Publicado: (2019)

Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study
por: Kei, Anastazia, et al.
Publicado: (2011)

Cholesteryl Ester Transfer Protein (CETP) Deficiency and CETP Inhibitors
por: Mabuchi, Hiroshi, et al.
Publicado: (2014)

Dyslipidemia Associated with Chronic Kidney Disease
por: Tsimihodimos, Vasilis, et al.
Publicado: (2011)

PCSK9 and carbohydrate metabolism: A double-edged sword
por: Filippatos, Theodosios D, et al.
Publicado: (2017)

Effects of increased body weight and short-term weight loss on serum PCSK9 levels – a prospective pilot study
por: Filippatos, Theodosios D, et al.
Publicado: (2017)

A novel swine model for evaluation of dyslipidemia and atherosclerosis induced by human CETP overexpression
por: Chen, Tao, et al.
Publicado: (2017)

Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin
por: Srisawasdi, Pornpen, et al.
Publicado: (2021)

LDL cholesterol estimation in patients with the metabolic syndrome
por: Gazi, Irene, et al.
Publicado: (2006)

The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits
por: Wu, Ben J., et al.
Publicado: (2019)

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
por: Metzinger, Mark P., et al.
Publicado: (2020)

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
por: Sammons, E, et al.
Publicado: (2021)

The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis
por: Dangas, Katerina, et al.
Publicado: (2022)

Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys
por: Brodeur, Mathieu R., et al.
Publicado: (2017)

Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans
por: Brodeur, Mathieu R., et al.
Publicado: (2022)

Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study
por: Filippatos, Theodosios D., et al.
Publicado: (2013)

A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination
por: Filippatos, Theodosios D.
Publicado: (2012)

Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP mice
por: van Eenige, Robin, et al.
Publicado: (2021)

CETP inhibitors and cardiovascular disease: Time to think again
por: Miller, Norman E
Publicado: (2014)

CETP inhibitor evacetrapib enters mouse brain tissue
por: Phénix, Jasmine, et al.
Publicado: (2023)

Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena?
por: Kumar, Ajoy, et al.
Publicado: (2010)

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
por: Landray, M.J., et al.
Publicado: (2017)

CETP Inhibition: Past Failures and Future Hopes
por: Kosmas, Constantine E., et al.
Publicado: (2016)

Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner
por: Echeverría, Patricia, et al.
Publicado: (2014)

How Anacetrapib Inhibits the Activity of the Cholesteryl Ester Transfer Protein? Perspective through Atomistic Simulations
por: Äijänen, Tarja, et al.
Publicado: (2014)

New Diterpenes from Cultures of the Fungus Engleromyces goetzii and Their CETP Inhibitory Activity
por: Wang, Yang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t1ue9lebajng237eulli0dsfcn